Roche: haemophilia drug significantly reduces bleeds
(CercleFinance.com) - Roche's Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis in patients with haemophilia A without factor VIII inhibitors, according to a phase III study whose results have been published in the New England Journal of Medicine.
Data from the study showed that Hemlibra prophylaxis administered subcutaneously every week or every two weeks significantly reduced treated bleeds by 96% and 97%, respectively, compared to no prophylaxis.
Results also showed that 55.6% of people treated with Hemlibra every week and 60% of people treated with Hemlibra every two weeks experienced zero treated bleeds, compared to 0% of people treated with no prophylaxis.
Hemlibra is currently under priority review by the FDA for people with haemophilia A without factor VIII inhibitors.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Data from the study showed that Hemlibra prophylaxis administered subcutaneously every week or every two weeks significantly reduced treated bleeds by 96% and 97%, respectively, compared to no prophylaxis.
Results also showed that 55.6% of people treated with Hemlibra every week and 60% of people treated with Hemlibra every two weeks experienced zero treated bleeds, compared to 0% of people treated with no prophylaxis.
Hemlibra is currently under priority review by the FDA for people with haemophilia A without factor VIII inhibitors.
Copyright (c) 2018 CercleFinance.com. All rights reserved.